CTRI/2021/06/033998已完成未知
An Open Label, Single-Arm, Multicentre, Clinical Study to Evaluate Efficacy and Safety of Anti-Dandruff Shampoo (HAMC-081905) in subjects with dandruff
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age: 18 to 60 years (both inclusive) at the time of consent.
- •2.Sex: Healthy male or non-pregnant/non-lactating female.
- •3.Female subjects of childbearing potential must have a negative urine pregnancy test performed on screening visit and Enrolment.
- •4.Subjects generally in good health and willing to give written informed consent and willing to follow study procedure.
- •5.Subjects with dandruff determined by ASFS score 24 to 48 with itching and flaking.
- •6.Subjects with visible flakes.
- •7.Subjects willing to refrain from using other products on the scalp other than those provided, including other shampoos/conditioners, scalp and hair treatment and oils/ products that has anti-dandruff action during the study period.
- •8.Subjects completing the conditioning phase.
- •9.Subjects willing to use test product throughout the study period.
- •10.Subjects must be able to understand and provide written informed consent to participate in the study.
- •11.Subjects should be willing and able to follow the study protocol to participate in the study.
排除标准
- •1)History of any dermatological conditions of the scalp (other than dandruff or seborrheic dermatitis) that would interfere with the diagnosis or assessment (e.g. psoriasis, eczema, atopic dermatitis, or other skin/scalp infections).
- •2)Subjects with excessive erythema, crusting or a significant number of pustules/papules on the scalp.
- •3)History of skin cancer or treatment for any type of cancer within the last 2 years.
- •4)History of prior use of antidandruff treatment on scalp within past 1 month.
- •5)Participation in a similar clinical study within the previous 90 Days.
- •6)Subjects with a history or present condition of an allergic response to dandruff shampoos or any cosmetic products or component present in the test product.
- •7)Any other condition which could warrant exclusion from the study, as per the Dermatologistââ?¬•s/investigatorââ?¬•s discretion
研究者
相似试验
已完成
不适用
Anti-Dandruff Shampoo Testing on healthy male and females adult subjects.CTRI/2021/06/034226The Himalaya Drug Company102
进行中(未招募)
不适用
A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid ArthritisEUCTR2014-004887-39-PLSamsung Bioepis Co., Ltd
尚未招募
4 期
A Clinical Investigation study in Indian population to evaluate the Safety and Efficacy of Los DelineTM for contour & volume correction of Human Soft Tissues.CTRI/2023/09/057513JCP International Private Limited
进行中(未招募)
1 期
Clinical trial in patients with advanced breast cancer (hormone receptor-positive, HER2-negative) receiving palbociclib and standard therapy with an aromatase inhibitor or fulvestrant after prior endocrine therapy.The study population includes postmenopausal patients with advanced (locally recurrent, inoperable and/or metastatic), HR+, HER2- breast cancer. For peri-/premenopausal patients, endocrine therapy has to be combines with a luteinizing hormone-releasinghormone (LRHR) agonist.MedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864MedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2015-001603-32-DEiOMEDICO AG360
Unknown
3 期
Clinical trial to determine the efficacy and tolerability of oral iron preparations in iron deficiency aneamia in pregnancyCTRI/2021/07/035277GC Chemie Pharmie Ltd4
